Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16523133 | 0.91 | LMNA (0.48) | KCNA5LMNAPOLBKDM4ANAMPT | |
| SCHEMBL13853697 | 0.89 | POLB (0.52) | KCNA5LMNAPOLBKDM4ANAMPT | |
| SCHEMBL28131286 | 0.88 | KCNA5 (0.50) | KCNA5LMNAPOLBKDM4ANAMPT | |
| SCHEMBL21483553 | 0.88 | HDAC1 (0.56) | KCNA5LMNAPOLBKDM4ANAMPT | |
| SCHEMBL6679107 | 0.88 | KCNA5 (0.46) | KCNA5LMNAPOLBKDM4ANAMPT | |
| SCHEMBL8018113 | 0.87 | KCNA5 (0.56) | KCNA5LMNAPOLBKDM4ANAMPT | |
| SCHEMBL30159605 | 0.87 | KCNA5 (0.56) | KCNA5LMNAPOLBKDM4ANAMPT | |
| SCHEMBL29991524 | 0.86 | POLB (0.50) | LMNAPOLBHDAC1RXFP1HDAC10 | |
| SCHEMBL13980716 | 0.86 | POLB (0.50) | LMNAPOLBHDAC1RXFP1HDAC10 | |
| SCHEMBL646870 | 0.84 | ALDH1A1 (0.50) | LMNAPOLBRXFP1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048877-B2 | Guanidine derivatives and their medical use | NEUROSEARCH A/S (DK) | 2011-11-01 | — | — | US | disclosed |
| US-20090099208-A1 | NOVEL GUANIDINE DERIVATIVES AND THEIR MEDICAL USE | ACESION PHARMA APS (DK) | 2009-04-16 | — | — | US | disclosed |
| WO-2007110363-A1 | NOVEL GUANIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099208-A1 | NOVEL GUANIDINE DERIVATIVES AND THEIR MEDICAL USE | KCNN2, KCNN1, KCNN3 | KCNA5 30/4885LMNA 1935/4885POLB 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.